Lumbrokinase

Technical Overview: Lumbrokinase

CAS: 556743‑18‑1
Type: Fibrinolytic enzyme complex (proteolytic enzymes derived from Eisenia fetida earthworms)
Form: Typically supplied as lyophilised powder or enteric‑coated granules
Activity: Fibrinolytic units (FU) or international units (IU), depending on supplier

Mechanism of Action (MoA)

Concise takeaway:
Lumbrokinase enhances fibrinolysis through direct fibrin degradation and plasminogen activation, making it a dual‑pathway fibrinolytic system.

Mechanistic detail:

• Direct fibrinolysis — Several isoenzymes within the lumbrokinase complex directly cleave fibrin, similar to plasmin‑like activity.
• Plasminogen activation — Some components act as plasminogen activators, converting plasminogen → plasmin, amplifying fibrin breakdown.
• Selective for fibrin‑rich environments — Exhibits higher activity in fibrin‑dense clots, reducing systemic bleeding risk compared to non‑selective fibrinolytics.
• Anti‑platelet effects (mild) — Inhibits platelet aggregation pathways, contributing to improved microcirculation.
• Anti‑inflammatory modulation — Downregulates inflammatory mediators associated with endothelial dysfunction (varies by preparation).

Applications

Primary domains:

• Cardiovascular support — Used in nutraceutical and adjunctive settings for improving blood flow and reducing fibrin burden.
• Hypercoagulability management — Applied in contexts involving elevated fibrinogen, D‑dimer, or microclot formation.
• Thrombotic risk reduction — Supports breakdown of fibrin networks associated with thrombosis.
• Microcirculation enhancement — Used in metabolic and inflammatory conditions where microvascular flow is impaired.
• Adjunctive enzyme therapy — Combined with nattokinase, serrapeptase, or bromelain in enzyme‑based formulations.

Industrial / research uses:

• Biochemical research on fibrinolytic pathways
• Enzyme formulation studies
• Comparative enzymology vs. plasminogen activators

Stability Profile

General stability characteristics:

• Lyophilised powder is stable at 2–8 °C for extended periods (12–24 months depending on supplier).
• Highly sensitive to moisture — humidity rapidly reduces enzymatic activity.
• Heat‑labile — activity declines significantly above 25–30 °C; denaturation accelerates at higher temperatures.
• pH sensitivity:
  • Optimal activity: pH 7.0–8.0
  • Degradation increases in acidic environments (hence enteric coatings for oral forms).
• Oxidation‑sensitive — exposure to oxygen and light can reduce activity; nitrogen‑flushed vials are common.

Reconstitution stability:

• Once reconstituted (for research use), stability is typically <24 hours at 2–8 °C.
• Freeze–thaw cycles destroy activity and must be avoided.

Storage Requirements

For bulk procurement (powder form):

• Temperature: 2–8 °C (refrigerated)
• Humidity: <40% RH; store in desiccated, sealed containers
• Light: Protect from light; amber vials or foil pouches recommended
• Atmosphere: Nitrogen‑flushed or vacuum‑sealed packaging preferred
• Shelf life: 12–24 months depending on supplier specifications

For finished formulations (capsules/tablets):

• Store at cool, dry conditions (15–25 °C)
• Avoid bathroom‑level humidity; moisture ingress destroys activity
• Enteric‑coated forms must not be crushed or opened due to acid sensitivity

Degradation Pathways (Operationally Relevant)

• Moisture → rapid loss of enzymatic activity
• Heat → irreversible denaturation
• Acid exposure → inactivation
• Oxidation → reduced potency
• Proteolytic self‑digestion if improperly stabilised